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screen for functional gastrointestinal disorders, serve as
inclusion criteria in clinical trials, and support epidemio-
logic surveys. Separate questionnaires were developed for
adults, children and adolescents, and infants and toddlers.
For the adult questionnaire, we first surveyed 1162 adults
without gastrointestinal disorders, and recommended the
90th percentile symptom frequency as the threshold for
defining what is abnormal. Diagnostic questions were
formulated and verified with clinical experts using a
recursive process. The diagnostic sensitivity of the ques-
tionnaire was tested in 843 patients from 9 gastroenter-
ology clinics, with a focus on clinical diagnoses of irritable
bowel syndrome (IBS), functional constipation (FC), and
functional dyspepsia (FD). Sensitivity was 62.7% for IBS,
54.7% for FD, and 32.2% for FC. Specificity, assessed in a
population sample of 5931 adults, was 97.1% for IBS,
93.3% for FD, and 93.6% for FC. Excess overlap among IBS,
FC, and FD was a major contributor to reduced diagnostic
sensitivity, and when overlap of IBS with FC was permitted,
sensitivity for FC diagnosis increased to 73.2%. All ques-
tions were understandable to at least 90% of individuals,
and Rome IV diagnoses were reproducible in three-fourths
of patients after 1 month. Validation of the pediatric
questionnaires is ongoing.Abbreviations used in this paper: FC, functional constipation; FD, func-
tional dyspepsia; FGID, functional gastrointestinal disorders; IBS, irritableKeywords: Sensitivity; Specificity; Functional Gastrointestinal
Disorder; Irritable Bowel Syndrome; Functional Constipation;
Functional Dyspepsia.
he Rome working teams, which are composed ofbowel syndrome; OIC, opioid-induced constipation; QDC, Questionnaire
Development Committee; R4DQ, Rome IV Diagnostic Questionnaire.Tclinical investigators and clinicians who are ex-
perts in the functional gastrointestinal disorders (FGIDs)
that affect specific regions of the gut, devise diagnostic
criteria for these disorders that are intended for use by
other clinicians and researchers (not patients). Their goal
is to make the criteria as sensitive and specific as possible,and to accomplish this they sometimes develop complex
diagnostic algorithms and combine requirements for lab-
oratory evaluations with symptom criteria. However,
there is also a need for a questionnaire that translates the
diagnostic criteria into questions that are understandable
to most patients, in order to enable standardized diag-
nostic assessment of individuals. Consequently, the Rome
Foundation appointed a Questionnaire Development
Committee (QDC) of individuals with expertise in test
development to develop a patient questionnaire that in-
corporates the Rome diagnostic criteria. These questions
can be used as inclusion criteria in clinical trials, as case
definitions in epidemiological surveys, or for clinic
screening.
The mandate of the QDC was to develop the Rome IV
Diagnostic Questionnaire for Adults based on the new Rome
IV criteria and to assess its performance with respect to
understandability by patients, testretest reliability,
concordance with independent diagnoses by experienced
clinicians, and ability to discriminate patients with the 3
most common FGIDs, which are irritable bowel syndrome
(IBS), functional constipation (FC), and functional dyspepsia
(FD), from nonpatient controls recruited from the popula-
tion. Two pediatric questionnaires were also developed by a
QDC subcommittee, but testing of these is still underway
and will not be described here.
The process of developing and validating the Rome IV
Diagnostic Questionnaire for Adults consisted of 5 different
project steps, and these will be described in sequence.
Step 1. Survey The Normal Frequency of
Occurrence of Gastrointestinal
Symptoms in the General Population of
the United States to Guide the Rome IV
Working Teams in Defining an
Abnormal Symptom Frequency
The symptoms that the Rome working teams identified 
as diagnostic of FGIDs are not pathognomonic for GI disease; 
they are symptoms such as abdominal pain, nausea, vom-
iting, and heartburn that also occur occasionally in healthy 
nonpatients. These symptoms are only considered clinically 
significant and indicative of an FGID if they occur at an 
abnormally high frequency. This observation has 2 impor-
tant consequences for the design of symptom-based diag-
nostic questionnaires: (1) the response scales used for 
questions about the frequency of symptom occurrence must 
have small enough steps to capture clinically significant 
differences between individuals, and (2) the thresholds used 
to define what is an abnormal frequency of occurrence will 
vary for different symptoms because the normal frequency 
of occurrence of these symptoms differs.
To address this, the QDC first developed and validated 
new response scales for the Rome IV diagnostic question-
naire, with more response steps than the Rome III.1 The 
committee then conducted a survey of a nationally repre-
sentative sample of US adults in order to provide the Rome 
IV working teams with the data needed to set thresholds for 
identifying meaningful, clinically significant deviations from 
the normal frequency of occurrence of GI symptoms. A 
sample of 1665 US adults stratified by sex (50% males), age, 
race, and ethnicity was recruited by a market research firm, 
CINT USA, Inc. (Los Angeles, CA) to complete an Internet 
survey. After inconsistent responders (identified by 3 
repeated survey questions) were eliminated, response sets 
from 1277 individuals were retained for analysis.
For the purpose of setting frequency thresholds for 
defining what should be considered abnormal, we identified 
the 90th percentile for all questions (males and females 
combined) and reported these to the committees as rec-
ommended thresholds. We reasoned that using these 
thresholds for diagnoses would result in no more than 10%
of healthy subjects being misclassified as patients, and when 
these 90th percentile thresholds were combined for multiple 
symptoms used to diagnose a disorder, the specificity could 
be expected to be in excess of 90%. In the calculation of 
these cutoffs, we excluded subjects who reported having a 
prior medical diagnosis of upper GI diagnoses from analysis 
of upper GI symptom thresholds, and conversely excluded 
those reporting lower GI diagnoses from analysis of lower 
GI symptoms.
Figure 1 illustrates how these data were analyzed: The 
cardinal symptom defining IBS is the frequency of abdom-
inal pain, and the figure shows a histogram of the frequency 
of all responses to the question on abdominal pain. If the 
threshold for clinical significance is set at once a week as the 
Rome IV Bowel Committee recommended, the proportion of 
these population controls who might be misclassified as IBSis only 6.7%, indicating that the specificity of this symptom
criterion for IBS diagnosis is 93.3%. Figure 1 also shows
how the specificity of the diagnosis would be impacted if an
alternative threshold for clinical significance were selected,
and it shows that abdominal pain or discomfort is reported
significantly more frequently by females than by males.
Because males have a lower prevalence of abdominal pain
and discomfort than females, the 90th percentile for males
could be set at 2 to 3 days per month rather than once a
week, and the 90th percentile for females occurs once a
week, as is the case for the combined sample. For simplicity,
the QDC recommended that the frequency thresholds for
IBS diagnosis should be based on the 90th percentile for
women and men combined.
A summary report2 on the distribution of symptom
occurrence rates for all the Rome III symptoms was
distributed to the Rome IV working teams together with
recommendations for selecting frequency thresholds for
diagnosis. This report is available as a supplement to this
article. Most of the working teams adopted these
suggestions.Step 2. Development of the Rome IV
Diagnostic Questionnaire for Adults
The 6 working teams that were tasked with updating the
Rome diagnostic criteria for the FGIDs in each region of the
GI tract were appointed in 2013 and were requested to
complete draft documents, including revised diagnostic
criteria by May 2014. These committees worked by e-mail
and conference calls, and met together for the first time at a
satellite meeting held in conjunction with Digestive Disease
Week 2014. Previous to this, the QDC completed its survey
of the base rates of symptom occurrence in the population
and also revised and validated new, more sensitive response
scales1 for patients to use when reporting their symptoms.
The QDC developed a draft of the Rome IV Diagnostic
Questionnaire (R4DQ) and distributed the questions
appropriate to each region of the GI tract to the chair and
co-chair of the working teams immediately before 3-day
meetings of all the committees in December 2014. The
chair and co-chair of the QDC met with each committee to
discuss how well the draft diagnostic questions embodied
the revised diagnostic criteria.
The QDC’s interactions with the working teams were
iterative: When the working teams revised their diagnostic
criteria based on feedback from the Rome Foundation’s
Editorial Committee, or the critiques submitted by outside
reviewers, the QDC revised the draft diagnostic questions.
After each revision to either the diagnostic criteria or the
diagnostic questions, the QDC asked the committees to again
review the diagnostic questions for consistency with the
diagnostic criteria.
Translatability Assessment
When the QDC was confident that the diagnostic ques-
tionnaire was in a near-final form, it was submitted to the
professional translation company, Transperfect Inc. (New
Figure 1. This figure 
shows a histogram of the 
frequency of occurrence of 
“discomfort or abdominal 
pain” in the general popu-
lation after excluding 
subjects with physician-
diagnosed lower gastroin-
testinal disorders. The 
dotted vertical line shows 
the recommended 
threshold that is 90th 
percentile for the com-
bined male and female 
sample. MT, shows the 
90th percentile for males; 
FT, the 90th percentile for 
females.York, NY), for an assessment of the translatability into the
following major languages: Arabic, French, German, Hindi,
Italian, Japanese, Korean, Russian, and simplified Chinese.
This translatability assessment resulted in no changes to the
English version of the questionnaire, but did provide guid-
ance that will be useful to the translators when the Rome IV
questionnaire is translated into these and other languages.Step 3: Understandability Assessment
In order to assess the understandability of the R4DQ, the
QDC recruited a new US general population sample of 589
adult subjects stratified by sex, age, race, ethnicity, and
years of education to complete an Internet survey. Each
subject was asked to evaluate one-third (approximately 28)
of the total questions. Subjects first answered each symptom
question and were then asked (1) whether the question was
difficult to understand (yes or no) and, if the question was
difficult, (2) what about the question made it difficult to
understand and (3) to give suggestions for alternative more
understandable wording. On average, 1.5 questions of 28
were rated as difficult to understand, and neither older age
nor fewer years of education were associated with the
number of questions rated difficult to understand. Seven
questions were rated difficult by 10% or more subjects, and
these were revised to enhance their simplicity and clarity
based on the suggestions of the subjects. The QDC
concluded that all questions in the final form of the R4DQ
are understandable to >90% of US adults, and that under-
standability is not influenced by age or education.
Final Reconciliation Between the Questionnaire
and Working Team Criteria
After completing the understandability and trans-
latability analyses and making minor changes to thequestionnaire, the chair and co-chair of the QDC committee
again compared the questions with the Rome IV diagnostic
criteria and developed scoring criteria for assigning provi-
sional diagnoses based on questionnaire responses. This
review identified a need for the working teams to make
minor changes to the wording of the diagnostic criteria to
ensure agreement with the questionnaire, and these sug-
gestions were communicated to the working teams and
incorporated into the Rome IV diagnostic criteria.Step 4. Clinical Validation of the English
Version of the Diagnostic Questionnaire
The preferred method for assessing the accuracy of a
new diagnostic test is to compare classifications based on
the new test to classifications based on an objectively
measured biological marker that is known to be related to
the pathophysiology of the disease. However, this is not
possible for the FGIDs because there is no consensus on
specific pathophysiological mechanisms for them, and no
biomarkers exist that can identify the FGIDs with acceptable
precision.3 Another barrier to validation of symptom criteria
for the FGIDs is that similar symptoms (eg, abdominal pain,
nausea, vomiting, constipation, and diarrhea) are present in
other diseases; examples are inflammatory bowel disease,
gastroesophageal reflux disease, celiac disease, and GI can-
cers. Many view the exclusion of other disease explanations
for symptoms as necessary for the diagnosis of the FGIDs.
In the absence of an objective reference standard for
diagnosis of FGIDs, 2 models of validation have been used4:
In the first model, the reference standard is a negative
endoscopy, alternative imaging study, or laboratory test to
exclude other diseases that could cause the symptoms, and
the measure of diagnostic accuracy is whether the symptom
criteria correctly identify patients who do not have an
alternative basis for their symptoms.5,6 The second model 
uses positive diagnoses made by experienced clinicians as 
the reference standard, and the measure of diagnostic ac-
curacy is whether the symptom criteria are concordant with 
the clinical diagnosis.7,8 A third model is a hybrid of the first 
2; for example, Vanner et al9 first excluded from consider-
ation any patient with alarm signs or symptoms suggestive 
of possible structural disease (eg, blood in stools or family 
history of GI cancer) and then examined the agreement of 
the Rome II symptom criteria with clinical diagnosis; he 
found that the positive predictive value of the Rome II 
criteria was 100%.
The QDC utilized a hybrid model for validation of the 
criteria for IBS and FD: To be included as a reference case of 
IBS, patients must have had a negative endoscopy within the 
last 5 years as well as a positive clinical diagnosis; and to be 
included as a reference case of FD, patients must have had a 
negative upper endoscopy within the last 5 years plus a 
positive clinical diagnosis. However, red flag signs or alarm 
symptoms, such as blood in stools or a family history of 
colon cancer, did not result in exclusion of the patient.
Aims of the Clinical Validation Study
The primary goal of the validation study was to test the 
sensitivity of the R4DQ for identifying patients who were 
diagnosed IBS, FC, or FD by clinicians. These reference 
clinical diagnoses were made by experienced clinicians 
before the patients completing the R4DQ, thus guaranteeing 
that the reference diagnoses were independent. In addition, 
a diagnosis of IBS required that the patient have a colo-
noscopy within the last 5 years, and a diagnosis of FD 
required that the patient have an upper endoscopy within 
the same time frame. Additional goals of this study were to 
assess the testretest reliability of the R4DQ by having 
approximately 30 patients at each site complete the R4DQ a 
second time after a 30-day interval, and to examine the 
overlap between FGIDs diagnosed by the R4DQ.
Methods
The study was conducted at 9 clinical sites managed by 
academic gastroenterologists who are familiar with the 
FGIDs and with previous versions of the Rome criteria. Each 
site was asked to recruit 100150 patients, including 25%
with a clinical diagnosis of IBS, 25% with a clinical diagnosis 
of FC, 25% with a clinical diagnosis of FD, and 25% with 
other FGID diagnoses. The purpose of concentrating 
recruitment on IBS, FC, and FD was to insure that sufficient 
numbers of patients could be recruited to have adequate 
statistical power to test sensitivity. These are the most 
common FGID diagnoses made in clinical practice.
Inclusion/Exclusion Criteria
To participate, subjects were required to have been 
diagnosed with an FGID in a medical clinic, have personal 
access to an Internet-connected computer or tablet and be 
able to use it to answer questionnaires online; be able 
read and write English fluently; be at least 18 years old; 
have had GI symptoms for at least 6 months; and for thesubsample of patients with IBS or FD clinical diagnosis,
have had an endoscopy (colonoscopy for IBS, upper GI
endoscopy for FD) with negative findings within the past 5
years. Individuals who had been diagnosed with the
following organic health problems likely to affect GI
symptoms were excluded from participation in the study:
inflammatory bowel disease (Crohn’s disease or ulcerative
colitis), cancer anywhere in the GI tract, current infection
of the GI tract, celiac disease, diabetes mellitus, and/or an
eating disorder. Individuals who had undergone bariatric
surgery or resection of any part of their bowels except
appendix or gallbladder operations were also excluded
from participation.Enrollment and Questionnaire Completion
The research coordinator at each site reviewed the
medical records for the past 36 months to retrospectively
identify all patients assigned a clinical diagnosis of any FGID.
At sites where this retrospective medical record review did
not yield enough patients in all categories, prospective
enrollment of new patients was permitted. Enrollment and
data collection occurred between April 1 and September
15, 2015.
Research coordinators at the clinical sites sent e-mails or
letters to eligible patients explaining the purpose of the
study. Subjects were given the web address where they
could complete the questionnaire and, to ensure that the
database contained no information that could be used to
identify them, they were assigned a randomly selected ID
and a unique password to enter when they took the ques-
tionnaire. When potential study participants accessed the
study website, they first reviewed a study description and
recorded their consent before completing the online study
questionnaire.
The questionnaire included the Rome IV Diagnostic
Questionnaire (from 26 to 86 questions depending on skip
patterns); the Rome III Diagnostic Questionnaire modules
for IBS, FC, and FD (up to 27 questions); 6 demographic
questions; and 6 questions about the frequency and types of
medications used for GI symptoms. They were also asked
about excluded diagnoses to confirm eligibility. Completion
of the online questionnaires required 15 to 20 minutes, and
patients received $25 for participation.
The research coordinator at each site had access on the
study website to a password-protected study-management
interface to view a list of the IDs of all patients from their
site who had completed the questionnaire. The coordinators
were encouraged to contact all subjects who had not
completed the questionnaires within 2 weeks to remind
them to do so.
Research coordinators entered the primary FGID clinical
diagnosis (reference diagnosis) into the website interface
for all subjects who completed the questionnaire. The co-
ordinators also reviewed the medical records of question-
naire completers and abstracted data on all other GI
diagnoses and relevant medical tests, such as endoscopy,
transit study, gastric emptying study, esophageal pH study,
esophageal manometry, barium enema or magnetic
resonance imaging of the colon, and fecal stool test for ova/
parasites.
The research coordinators randomly selected a subset 
of questionnaire completers with clinical diagnoses of IBS, 
FD, and functional constipation and invited them to com-
plete the questionnaire a second time 30 days after the 
first completion, for an additional payment of $25. Re-
minders to complete the repeat test were sent by e-mail as 
needed.Table 1.Frequency of All Clinical Functional Gastrointestinal
Disorder Diagnoses in the Sample of 843
Gastrointestinal Patients, Including Multiple
Diagnoses for the Same Patient
FGID diagnosis No. of cases
% of Total
sample
Irritable bowel syndrome 442 52.4
Functional constipation 235 27.9
Functional dyspepsia 153 18.1
Functional bloating 96 11.4
Functional diarrhea 79 9.4
Functional abdominal pain 71 8.4
Functional fecal incontinence 55 6.5
Chronic idiopathic nausea 34 4
Dysphagia 13 1.5
Globus 11 1.3
Functional heartburn 11 1.3
Functional vomiting 9 1.1
Unspecified belching 7 0.8
Cyclic vomiting 7 0.8
Functional chest pain 5 0.6
Proctalgia fugax 3 0.4
Rumination syndrome 2 0.2
Sphincter of Oddi dysfunction 2 0.2
Chronic proctalgia 2 0.2
Aerophagia 1 0.1
Levator ani 1 0.1Data Analysis
For the primary analysis of diagnostic test sensitivity, 
the data from all clinical sites were pooled. Sensitivity and 
95% confidence intervals for sensitivity were computed for 
each diagnosis (IBS, FC, and FD) separately. Sensitivity was 
defined as the proportion of all patients with a primary 
clinical diagnosis of the index disorder who fulfilled Rome 
IV criteria for the same diagnosis based on questionnaire 
responses. Patients receiving a secondary clinical diagnosis 
of the index disorder were excluded from the analysis due 
to a concern that clinicians may vary in the amount of time 
and effort devoted to secondary diagnoses in a busy clinic 
and may make secondary diagnoses of IBS or FD without 
endoscopy, thus causing secondary diagnoses to be less 
reliable.
Specificity, which is defined as the proportion of all 
patients without the index clinical diagnosis who also do 
not fulfill Rome IV questionnaire criteria for the index 
diagnosis, was not a goal of the analysis of data collected 
from the clinical sites for the following reasons: (1) The 
ability to discriminate patients with the index FGID from 
patients with other FGIDs is less relevant to the perfor-
mance of the diagnostic questionnaire than is the ability to 
discriminate true cases from general population controls 
because it is known that there is a high degree of overlap 
between FGIDs in specialty medical clinics. (2) The design 
of the study was not appropriate for estimating the ability 
to discriminate the index disorder from other FGIDs even in 
the medical clinic because the patient sample was not 
representative of the clinic population; instead, patients 
were selectively recruited based on having established 
clinical diagnoses of specific FGIDs. Consequently, we esti-
mated specificity of the Rome IV criteria from a large, 
representative population sample (see Three Country 
Population Survey), which was recruited specifically for 
this purpose.
Secondary sensitivity analyses were performed to assess 
the influence of symptom frequency thresholds and other 
specifics of the diagnostic criteria on test accuracy. Addi-
tionally, the degree of overlap between FGID diagnoses 
based on Rome IV criteria was calculated. In this analysis, all 
FGID diagnoses (primary and secondary) recorded in the 
medical record were included. Testretest reliability was 
assessed for each of the 3 key FGID diagnoses in the study 
by computing percent agreement and k statistics between 2 
administrations of the questionnaire to the same subjects 
approximately 1 month apart, for each of the 3 primary 
diagnoses separately.Results
A total of 881 patients enrolled and completed the study
questionnaire across the 9 sites, but 38 were disqualified
because they were found not to meet study criteria after
enrollment, leaving 843 for analysis. Females comprised
76.3% of the 843 evaluable patients, and age ranged from
18 to 81 years (mean 43.6 years). Race/ethnicity distribu-
tion was 85.3% white, 4.3% black, 4.5% Asian, and 6.0%
other or not disclosed. Among US patients, 8.2% reported
Hispanic ethnicity. Table 1 shows the frequency of all FGID
clinical diagnoses (not Rome IV diagnoses based on the
questionnaire) found in the medical records of the 843
patients in the analysis sample.Sensitivity of the Rome IV Criteria
Columns 13 in Table 2 show the sensitivity statistics
for the 3 most prevalent FGIDS: IBS, FC, and FD. (The data
on specificity in columns 45 come from the Three Country
Population Survey and will be discussed later.)
Irritable bowel syndrome: sensitivity ana-
lysis. The sensitivity of the Rome IV criteria for IBS is
comparable with levels previously reported for Rome III,4
but is suboptimal. The QDC examined the impact on diag-
nostic sensitivity of each of the 3 changes made to the Rome
III criteria:
1. The threshold frequency of abdominal pain was made
more stringent, changing from 23 days per month in
Rome III to at least once a week in Rome IV. If the
frequency of abdominal pain was relaxed to 23 days
Table 2.Sensitivity and Specificity of the 3 Most Common Functional Gastrointestinal Disorders
Diagnosis
Clinical validation sample Population control sample
Sensitivity, % 95% CI Specificity, % 95% CI
IBS 62.7 57.867.6 97.1 96.697.6
FD 54.7 46.363.1 93.3 92.594.0
FC excluding OIC and IBS 33.9 27.040.8 94.5 93.995.2
FC including OIC and IBS 70.5 63.877.2 93.1 92.593.9
CI, confidence interval.per month and all other Rome IV criteria remained
the same, this would increase the sensitivity of Rome
IV to 69.9%.
2. “Discomfort” was dropped from the key qualifying
symptom, “abdominal discomfort or pain”; Rome IV
requires “abdominal pain.” However, this more
restrictive phrasing did not reduce diagnostic sensi-
tivity: The proportion of patients with a primary
clinical diagnosis of IBS who reported “abdominal
discomfort or pain” at least weekly on the Rome III
pain question was similar to the proportion who re-
ported “abdominal pain” at least weekly on the
equivalent Rome IV question (74.9% vs 78.4%
respectively).
3. Rome III required that pain or discomfort improve
after defecation and that changes in stool frequency
and/or consistency occur “when the pain started.” By
contrast, Rome IV requires only that pain and defe-
cation are “associated” in time or that changes in stool
consistency and frequency are “associated” with
abdominal pain. However, this change did not have a
significant impact on the sensitivity of the Rome
criteria.
To understand the causes of misclassifications in IBS, we
examined which Rome IV diagnoses were assigned by the
questionnaire to the 140 patients who received a clinical
diagnosis of IBS but did not meet Rome IV criteria for IBS.
The most common Rome IV diagnoses were FC (35 of 140),
FD (34 of 140), functional diarrhea (22 of 140), and levator
ani syndrome (20 of 140). We also tabulated the clinical
diagnoses assigned to 192 patients who met the Rome IV
criteria for IBS but did not receive a clinical diagnosis of IBS
by their physician. The most common clinical diagnoses
(either primary or secondary diagnosis) were FC (95 of
192), FD (58 of 192), functional bloating (27 of 192),
functional abdominal pain (25 of 192), and functional
diarrhea (17 of 192). These data show that the core symp-
toms that combine to diagnose IBS are the ones accounting
for most misclassifications, and they suggest that clinicians
likely base their clinical diagnoses on the predominant or
most bothersome symptom when patients present with the
constellation of constipation, diarrhea, abdominal pain, and
bloating. A significant number of misclassifications also
result from the overlap of FD with IBS.Functional dyspepsia: sensitivity analysis. The
Rome IV criteria for unspecified FD had a sensitivity of
54.7% (Table 2). Sensitivity was defined as the proportion
of patients with a physician primary diagnosis of FD who
fulfilled Rome IV criteria for unspecified FD, a Rome IV
diagnosis that requires that the patient meet symptom
criteria for either postprandial distress syndrome or
epigastric pain syndrome. Only patients who had an upper
endoscopy were included in this analysis. It was not
possible to examine the sensitivity of the questionnaire for
diagnosing postprandial distress syndrome and epigastric
pain syndrome because clinicians usually did not distin-
guish between these subtypes of FD.
To understand the causes of misclassifications in FD, we
examined the other Rome IV diagnoses assigned to 63 clinic
patients who received a clinical diagnosis of FD, but did not
meet Rome IV criteria for FD. The most common Rome IV
diagnoses were unspecified functional bowel disorder (20 of
63) and IBS (19 of 63). To further explore the causes of
misclassification, we examined the medical diagnoses
assigned to 308 patients who met the Rome IV criteria for
FD, but did not receive a clinical diagnosis of FD by their
physician. The most common clinical diagnoses (either pri-
mary or secondary diagnosis) were IBS (172 of 308), FC
(102 of 308), functional bloating (37 of 308), and functional
abdominal pain (32 of 308). These analyses suggest that
patients in whom FD symptoms overlap the symptoms of
IBS or constipation are the ones more likely to be
misclassified.
Functional constipation: sensitivity analysis. The
Rome IV criteria for FC require that patients meeting
symptom criteria for opioid-induced constipation (OIC) and
IBS be excluded from the diagnosis of FC. When this is done,
the sensitivity of the Rome IV criteria for identifying clini-
cally diagnosed FC is only 33.9%, which indicates that cli-
nicians are classifying many more patients as FC than are
being classified FC by the Rome IV criteria. However, when
the Rome IV criteria were relaxed to permit patients with
OIC and IBS to be classified as FC if they met the other FC
criteria (ie, when comorbid diagnoses were permitted), the
sensitivity increased to 70.5% (Table 2).
To understand the causes of misclassifications in FC, we
examined which Rome IV diagnoses were assigned by the
questionnaire to the 121 patients who received a clinical
diagnosis of FC but did not meet Rome IV criteria for FC. The
most common Rome IV diagnoses were IBS (84 of 121), FD
(67 of 121), proctalgia fugax (28 of 121), and levator ani 
syndrome (21 of 121). We also tabulated the clinical di-
agnoses assigned to 55 patients who met the Rome IV 
criteria for FC but did not receive a clinical diagnosis of FC 
by their physician. The most common clinical diagnoses 
(either primary or secondary diagnosis) were IBS (39 of 55), 
FD (12 of 55), and functional bloating (10 of 55). These data 
show that two-thirds of the misclassifications are due to the 
overlap of IBS with symptoms of FC, and the requirement 
that a patient meeting criteria for IBS cannot be assigned a 
diagnosis of FC.
We infer from this that the clinicians in our study were, 
for the most part, not behaving as if a diagnosis of IBS or OIC 
rules out a clinical diagnosis of FC. Such behavior is 
consistent with statements in the Rome IV Bowel Disorders 
chapter that FC and constipation-predominant IBS 
frequently overlap and should be seen as parts of a spec-
trum rather than as distinct disorders. This view is also 
supported by recent studies showing that the symptoms of 
FC and constipation-predominant IBS frequently over-
lap10,11 and, over time, many patients transition back and 
forth between these 2 diagnostic categories.11 Therefore, a 
major cause of low sensitivity for the FC criteria is that the 
Rome IV criteria do not permit FC to overlap with IBS-C and 
OIC.
Overlap of Rome IV Diagnoses of Irritable Bowel 
Syndrome, Functional Dyspepsia, and 
Functional Constipation
Table 3 shows the overlap between Rome IV diagnoses 
in the clinical validation study. This is a complex table 
because it shows the prevalence of each diagnosis in pa-
tients with each of the other 2 diagnoses and enables the 
reader to compare this overlap with the prevalence of the 
separate diagnoses. For example, the cell in the second row 
of the third column shows that 66.9% (257 of 384) patients 
with FD have IBS, which is greater than the prevalence of 
IBS in the whole sample (50.7% [427 of 843 patients]). 
Conversely, the cell in the third row of the second columnTable 3.Overlap Between Rome IV Diagnoses of Irritable Bowe
Constipation in the Clinic Validation Study (Irritable Bo





IBS — 66.9a (257
FD 60.2b (257/427) —
FC 37.7b (161/427) 39.0b (150
Total sample 50.7b (427/843) 45.6b (384
Note: Data are presented as % (n/N).
aPercent of patients with the diagnosis in the column heading w
the second row, third column, 66.9% (257/384) patients with FD
in the total clinical validation sample (column 5) of 50.7%.
bPercent of patients with the diagnosis in the row heading who a
the third row, second column, 60.2% (257/427) patients with IBS
sample of 45.6% (row 5).shows that 60.2% (257 of 427) of patients with IBS also
have FD, which is greater than the prevalence of FD in the
total sample (45.6% [384 of 843 patients]). The degree of
overlap among the other combinations of diagnoses shows a
similar excess overlap. This excess overlap in the symptoms
of IBS, FD, and FC is consistent with the sensitivity analyses
shown previously that identified the overlap among the
symptoms of these disorders as a factor that consistently
contributes to lower sensitivity for the diagnostic criteria.TestRetest Reliability of the Rome IV Diagnostic
Questionnaire for Adults
A subsample of the clinic patients completed retests with
the diagnostic questionnaire approximately 1 month after
the first administration. Percentage agreement between the
2 administrations was assessed with regard to the 3 key
diagnoses. Only data from the 140 patients who completed
the questionnaire the second time within a range of 2040
days after the first one were included in the analysis. Mean
time interval between administrations was 31.1 days. The
agreement between the first and second questionnaire
administration for the diagnoses was 75.7% for IBS (k ¼
0.51), 76.4% (k ¼ 0.53) for FD, and 79.2% (k ¼ 0.44) for FC
(k values in the range from 0.41 to 0.60 are considered
indicative of moderate agreement).12Step 5. Assessment of Specificity,
Prevalence, and Overlap of Functional
Gastrointestinal Disorder Diagnoses in
the Three Country Population Survey
Study Aims
The primary aims of this survey were to estimate the
specificity of the Rome IV criteria for distinguishing patients
with the 3 most common FGID diagnoses (IBS, FC, and FD)
from healthy population controls, to estimate the prevalence
in the population of the FGIDs based on Rome IV criteria,l Syndrome, Functional Dyspepsia, and Functional
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also had FD, compared with a prevalence of FD in the whole
Table 4.Demographic characteristics of the analysis sample








1949 1988 1994 5931
Sex, %
Female 49.4 49.3 48.9 49.2
Male 50.6 50.7 51.1 50.8
Age groups, %
1839 y 38.7 39.2 38.9 38.9
4064 y 40.5 40.1 40.4 40.4
65þ y 20.9 20.6 20.7 20.7
Years of education, %
<13 34.6 33.8 37.1 35.2
1316 49.2 44.6 42.0 45.2
>16 16.2 21.6 20.9 19.6
Race/ethnicity, %
Asian 1.9 9.1 3.1 4.7
Black 20.2 1.8 1.2 6.6




Other/mixed 2.1 4.0 1.8 2.6
Missing race informationa 0.0 9.9a 10.2a 6.7a
aRace/ethnicity data were collected in the Canadian and UK
samples only after the initial pilot sampling that amounted to
10% of the total final sample.
 
Methods
Qualtrics Inc. (Provo, UT), a global survey research 
company, was commissioned to identify nationally repre-
sentative general population samples of adults based on 
specific demographic quotas in the United States, English-
speaking Canada, and the United Kingdom. Recruitment 
was stratified based on sex, age, years of education, race, 
and, for the US sample, Hispanic ethnicity. Qualtrics directed 
interested subjects to the study website at the University of 
North Carolina at Chapel Hill for survey completion.
The survey included up to 86 R4DQ questions 
(depending on skip pattern); up to 27 questions from the 
IBS, FC, and FD modules of the Rome III Diagnostic Ques-
tionnaire; 15 questions from the Physical Health Question-
naire13; 8 questions from the SF-8 Health Survey14; 15
demographic questions; 8 questions on medical history; 4 
questions on access to health care; 1 question on diet; and 3 
questions on psychological distress related to GI symptoms. 
The median completion time for the survey was 19 minutes.
A total of 6300 respondents completed the survey in the 
3 countries, 2100 in each country. Subjects who self-
reported on the questionnaire that they had been diag-
nosed with inflammatory bowel disease, celiac disease, or GI 
cancer, or who had undergone GI resection except gall-
bladder or appendix, were excluded from analysis. An 
additional 369 (5.9%) who failed data-quality checks were 
also excluded, leaving 5931 valid response sets for statis-
tical analysis. The demographic characteristics of this anal-
ysis sample are presented in Table 4.Data Analysis
A primary aim for the Three Country Population Survey 
was to estimate the specificity of the Rome IV criteria for 
distinguishing patients with the 3 primary FGID diagnoses 
(IBS, FC, and FD) from healthy population controls. Those 
results are presented in Table 2. For each index diagnosis of 
an upper GI disorder, we first eliminated subjects who re-
ported a relevant upper GI medical diagnosis, and then 
calculated the proportion of these nonpatient population 
controls who did not fulfill the Rome IV diagnostic criteria 
for the index disorder. Similarly, for each index diagnosis of 
a lower GI disorder, we eliminated subjects who reported a 
relevant lower GI medical diagnosis and then calculated the 
proportion of these nonpatient population controls who did 
not fulfill the Rome IV diagnostic criteria for the index lower 
GI FGID. The prevalence estimates (as distinct from speci-
ficity estimates) were performed on all available subjects, 
including those with self-reported medical GI diagnoses. 
These estimates of specificity and prevalence were per-
formed on the pooled samples from all three countries. A 
third aim of the Three Country Population Survey was to 
estimate the overlap between the 3 most common FGIDs 
(IBS, FD, and FC) in the general population. For these ana-
lyses, subjects with IBS could also be diagnosed with FC.Results
Estimates for the population prevalence of the FGIDs and
the estimated specificity of a Rome IV diagnosis of each
FGID are given in Table 5.Overlap Between Irritable Bowel Syndrome,
Functional Constipation, and
Functional Dyspepsia
Table 6 shows the overlap among the 3 most common
FGIDs. The overlap among all pairs of FGID diagnoses is 36
times the prevalence of these diagnoses in the population.Development and Validation
of the Pediatric Rome IV
Diagnostic Questionnaires
In contrast to the adult questionnaire, where one version
is used to assess all patients, several different assessments
are available for the pediatric population. The Questionnaire
on Pediatric Gastrointestinal Symptoms was first developed
to measure Rome II criteria in children and adolescents
(aged 418 years), and updates were made for Rome III.
Questionnaires for both parents and children (aged 10 years
and older) were developed, and evidence exists for their
reliability and validity.1518 In addition, an infant/toddler
version was developed and tested recently, based on
parental report of infant/toddler symptoms.19 The mandate
of the pediatric subcommittee of the QDC was to update
Table 5.Population Prevalence of the Rome IV Functional Gastrointestinal Disorders in the Three Country General
Population Survey
Diagnosis Subjects, n Prevalence, %
Specificity, %
(95% CI)
Functional dysphagia 266 4.5 97.1 (96.797.6)
Functional heartburn 107 1.8 99.0 (98.799.3)
Reflux hypersensitivity 85 1.4 99.3 (99.199.6)
Globus sensation 61 1.0 99.1 (98.899.3)
Functional chest pain 59 1.0 99.2 (99.099.5)
Excessive belching 50 0.8 99.6 (99.499.8)
FD 551 9.3 93.3 (92.594.0)
Postprandial distress syndrome 454 7.7 94.2 (93.594.9)
Epigastric pain syndrome 212 3.6 98.0 (97.698.4)
Rumination 202 3.4 97.6 (97.298.1)
Chronic nausea and vomiting 80 1.3 99.0 (98.899.3)
Cyclic vomiting 71 1.2 99.2 (98.999.4)
Cannabinoid hyperemesis syndrome 10 0.2 99.9 (99.8100.0)
Functional biliary pain 12 0.2 99.9 (99.8100.0)
Central abdominal pain syndrome 1 0 —
Functional bowel disorder unspecified 752 12.7 88.4 (87.989.3)
FC excluding IBS and OIC 374 6.3 94.5 (93.995.2)
FC with IBS and OIC 525 8.9 93.2 (92.593.9)
IBS 341 5.7 97.1 (96.697.6)
OIC 88 1.5 99.2 (98.999.5)
FD 323 5.4 95.3 (94.795.9)
Functional bloating/distention 51 0.9 99.3 (99.199.6)
Proctalgia fugax 318 5.4 96.3 (95.896.9)
Levator ani syndrome 101 1.7 99.0 (98.799.3)
Fecal incontinence 196 3.3 98.0 (97.698.4)
CI, confidence interval.these questionnaires based on the Rome IV criteria. Reli-
ability and validity testing is currently ongoing, therefore,
the current article will only describe the development of the
questionnaire itself.
The committee followed procedures similar to those
described here for the Rome IV Diagnostic Questionnaire for
Adults, but with important exceptions: First, the newTable 6.Overlap Between Irritable Bowel Syndrome, Functiona






IBS — 31.6a (174
FD 51.0b (174/341) —
FC 30.8b (105/341) 22.0b (121
Total sample 5.7b (341/5931) 9.3b (551
Note: Data are presented as % (n/N).
aPercent of patients with the diagnosis in the column heading w
the second row, third column, 31.6% (174/551) patients with FD
in the total sample (column 5) of 5.7%.
bPercent of patients with the diagnosis in the row heading who a
the third row, second column, 51.0% (174/341) patients with IB
sample of 9.3% (row 5).response scales developed for the adult questionnaire were
not used in the pediatric questionnaires because they are
not appropriate for the cognitive developmental level of
children. For example, percentages can be difficult to un-
derstand and apply by children as young as age 10 years
old. Although the new response scales would be appropriate
for parental report, the committee desired to keep responsel Dyspepsia, and Functional Constipation in the General







/551) 20.0a (105/525) 5.7a (341/5931)
23.0a (121/525) 9.3a (551/5931)
/525) — 8.9a (525/5931)
/5931) 8.9b (525/5931) 5931
ho also have the diagnosis in the row heading, for example, in
also had IBS. This compares with an overall prevalence of IBS
lso have the diagnosis in the column heading, for example, in
S also have FD, compared to a prevalence of FD in the whole
scales similar for parents and children so that they can be 
compared in research and clinical practice. Secondly, 
because fewer resources were available for the validation of 
the 2 pediatric questionnaires, current validation efforts 
focus on comparison of questionnaire diagnoses with clin-
ical diagnoses, and the prevalence of Rome IV symptoms in 
a normal sample of US adults. These will be presented in 
another publication as data become available.This series of studies has several limitations:
1. The symptoms of the FGIDs fluctuate over time,20 and
there was a lapse of unknown duration between the
clinical diagnosis and the time the questionnaire was
completed. Treatment occurred during this interval,
and might have reduced the patient’s symptoms.
Testretest agreement over 1 month was about 75%,
which could be regarded as the upper limit of
Discussion
The studies presented here show that the Rome IV 
Diagnostic Questionnaire for Adults has adequate sensitivity 
and excellent specificity for IBS and FD diagnoses: for IBS, 
sensitivity was 62.7% and specificity was 94.5%; and for FD, 
sensitivity was 54.7% and specificity was 93.3%. For FC, on 
the other hand, the sensitivity of the diagnostic question-
naire was inadequate: sensitivity was 33.9% and specificity 
was 93.6%. The poor performance of the diagnostic ques-
tionnaire for FC was related to the Rome IV requirement 
that patients meeting criteria for IBS or OIC be excluded 
from the diagnosis of FC. When these exclusions were 
removed, 70.5% of the patients given a clinical diagnosis of 
FC were identified by the questionnaire.
We also showed that the questions on this diagnostic 
questionnaire are understandable to at least 90% of US 
adults and that comprehension of the questions is not 
significantly affected by older age or by limited education. 
Diagnoses of IBS, FC, and FD based on the questionnaire 
were reliable for three-fourths of clinic patients during a 30-
day interval.
A unique strength of this series of studies was the in-
clusion of secondary analyses to identify the sources of 
misclassifications by the diagnostic questionnaire: A major 
contributor to reduced sensitivity was revealed to be the 
overlap of symptoms related to IBS, FC, and FD. In partic-
ular, these sensitivity analyses suggest that FC and 
constipation-predominant IBS are on a continuum. This is 
consistent with recent research10,11 and with the opinions 
expressed by the Rome IV Bowel Committee, although it 
is not reflected in the Rome IV diagnostic criteria for IBS 
and FC.
The sensitivity of the Rome IV Diagnostic Questionnaire 
for Adults for identifying patients with IBS was also influ-
enced by the threshold frequency of abdominal pain 
required to make the diagnosis. The Rome IV criteria for IBS 
appear less sensitive than the Rome III criteria because 
Rome IV requires abdominal pain at least once a week, and 
Rome III required abdominal discomfort or pain only 23 
days per month.concordance between the clinical diagnosis and the
diagnostic questionnaire.
2. Another reason perfect agreement between clinical
diagnosis and a questionnaire-based diagnosis would
not be expected is that clinicians are able to consider
additional sources of information, such as physiolog-
ical tests, medical history, and family history, while
the questionnaire-based diagnosis relies exclusively
on the patient’s self-reported symptoms.
3. No effort was made to define the minimum diagnostic
workup at the participating clinical sites except for
the requirement that upper endoscopy was required
to diagnose FD and colonoscopy was required to di-
agnose IBS. Variations in practices between centers
might have resulted in heterogeneity of the reference
diagnostic groups.
4. Some Rome IV diagnoses now require physiological
tests (eg, disordered defecation), exclusion of
structural disease (eg, functional esophageal disor-
ders), physical examination findings (eg, tenderness
in levator ani syndrome), or physician judgment
(eg, whether abdominal pain has a central or a
peripheral cause in central abdominal pain syn-
drome) in addition to symptoms; these disorders
cannot be diagnosed by self-reported symptoms on
a questionnaire. Thus, not all of the Rome IV clas-
sification system can be validated by the study
design used here.
Despite these limitations, the studies described here
show that the R4DQ for adults has adequate sensitivity and
excellent specificity for the diagnosis of IBS, FD, and many of
the other FGIDs. The R4DQ is understandable to 90% of
patients, and diagnoses based on the questionnaire show
good testretest reliability. The Diagnostic Questionnaire is
also translatable to other languages, and this should make it
possible to carry out cross-cultural and global epidemiologic
studies. Future studies should allow, rather than arbitrarily
excluding, the overlap of symptoms of IBS, FC, and FD and
should explore the implications of this overlap for diag-
nostic classification and treatment.References
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